anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Bombesin (68Ga)
Trial phase: Phase 2
SMILES: CC(C)CC(NC(=O)CC(O)C(CC(C)C)NC(=O)C(Cc1cnc[nH]1)NC(=O)CNC(=O)C(NC(=O)C(C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(Cc1ccccc1)NC(=O)CN1CCC(NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)CC1)C(C)C)C(N)=O.[Ga+3]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: Patients receive 68Ga-RM2 IV. Within 45-60 minutes, patients undergo a PET/CT scan. Patients may undergo a second PET/CT scan immediately after the first scan for attenuation correction. Patients may undergo also a repeat 68Ga-RM2 PET/CT scan after the completion of their treatment to evaluate response to therapy, if requested by the treating physician.

Computed Tomography: Undergo PET/CT

Gallium Ga 68-labeled GRPR Antagonist BAY86-7548: Given IV

Laboratory Biomarker Analysis: Correlative studies

Positron Emission Tomography: Undergo PET/CT
Eligibility criteria:
Inclusion Criteria:

Biopsy proven prostate adenocarcinoma
Planned prostatectomy with lymph node dissection
Intermediate to high-risk disease (as determined by elevated PSA [PSA > 10], T-stage [T2b or greater], Gleason score [Gleason score > 6] or other risk factors)
Able to provide written consent
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Diagnostic CT or magnetic resonance imaging (MRI) performed within 30 days prior to the 68Ga-RM2 PET

Exclusion Criteria:

Inability to lie still for the entire imaging time (approximately 30 minutes)
Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
Intervention: Ketamine
Trial phase: Phase 2 | Phase 3
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 195
Group description: Treatments will be given 2 times a week up to a total of 6 treatment over 3 - 5 weeks. Initial standard dose will be 0.5 mg/kg infusion over 40 min. The dose can be modified if clinically warranted per investigator and patient discretion.

Ketamine: Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
Eligibility criteria:
Inclusion Criteria:

Written informed consent before any study related procedures are performed
Inpatients or outpatients referred by their providers for ECT treatment and eligible for ECT treatment
Males/females at least 21 years of age but no older than 75 years of age

Meet DSM-5 criteria for Major Depressive Episode as determined by both:

A. a clinician's diagnostic evaluation and B. confirmed with the MINI International Neuropsychiatric Interview (MINI 7.0.2)

A current depressive episode that has lasted a minimum of 4 weeks

Meet all of the following criteria on symptom rating scales at screening:

A. Montgomery Asberg Depression Rating Scale (MADRS) score >20 B. Young Mania Rating Scale (YMRS) of ≤ 5 C. Montreal Cognitive Assessment (MoCA) of ≥18

Have had ≥2 adequate trials of antidepressants or augmentation strategies during their lifetime. An adequate trial is defined as 4 weeks of medication at the minimum FDA approved dose. This will be equal to a trial rating of 3 or more.
In the opinion of the investigator, the patient is willing and able to comply with scheduled visits, treatment plan, and other trial procedures for the duration of the study

Exclusion Criteria:

Meet DSM-5 criteria for bipolar disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, mental retardation, or pervasive developmental disorder
Meets any exclusion criteria for ECT or ketamine treatment as described in the clinical guidelines or according to investigator judgment
The patient is pregnant or breast feeding
The patient has a severe medical illness or severe neurological disorder
The patient has a known ketamine allergy or is taking a medication that may interact with ketamine
Diagnosis of major depressive disorder with psychotic features during the current depressive episode
Unable to give informed consent
Was previously enrolled/randomized into the trial
Intervention: Tirofiban
Trial phase: Phase 4
ATC code: B01AC17
SMILES: CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h

Tirofiban
Eligibility criteria:
Inclusion Criteria:

diagnosed with NSTE-ACS who need PCI
loaded with aspirin and clopidogrel at least 6 h before the procedure

Exclusion Criteria:

thrombocytopenia (platelet count <100,000/μL)
history of hemorrhagic stroke
history of ischemic stroke in the recent 2 year
history of major surgery 6 months prior
Intervention: Hydromorphone
Trial phase: Phase 4
ATC code: N02AA03 | N02AA53 | N02AG04
SMILES: [H][C@@]12CCC(=O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 46
Group description: Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone

Hydromorphone: Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
Eligibility criteria:
Inclusion Criteria:

Adult subjects aged 18 years or older
Scheduled for elective posterior lumbar spinal fusion surgery between 1 and 3 levels

Exclusion Criteria:

Baseline cognitive deficits sufficient to make objective pain self-assessments unreliable in the estimation of the Study Investigators.
Immunocompromised subject
Coagulopathy
Severe liver and renal dysfunction
Preoperative neurological deficits
The dura damage during surgery
Inability to follow directions or comprehend the English language.
Females who are pregnant as determined by positive pregnancy test on or before the day of surgery.
Prisoners.
Patient refusal to provide informed consent.
Allergy to amide local anesthetics (lidocaine, bupivacaine, ropivacaine) or opioid (fentanyl) allergy if patient assigned epidural analgesia.
Hydromorphone allergy if patient assigned IV PCA
Intervention: Triamcinolone
Trial phase: Phase 2
ATC code: A01AC01 | C05AA12 | D07AB09 | D07BB03 | D07CB01 | D07XB02 | H02AB08 | R01AD11 | R03BA06 | S01BA05 | S02CA04
SMILES: [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.

Triamcinolone: 6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
Eligibility criteria:
Inclusion Criteria:

Patients must have a histologically or cytologically confirmed cancer diagnosis for which EGFRI treatment is indicated
Initiation of topical steroids or control treatment within 3 days of initiation of cetuximab, erlotinib, panitumumab, or afatinib
Patients must be age ≥ 18 years.
Life expectancy of greater than 6 weeks
Patient able to use topical medications reliably and complete questionnaires with assistance if needed
Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study.

Exclusion Criteria:

Patients who have used systemic or topical steroids within 7 days of trial registration, or start systemic or topical steroids for reasons unrelated to trial during the 6-week follow up period
Patients who have used antibiotics within 7 days of trial registration, or start antibiotics for other conditions during the 6-week follow up period
History of allergic reactions to topical steroids
Patients with any rash at the time of study registration
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Patients using any other topical medications in the treatment areas (face, chest, or back).
Intervention: Sugammadex
Trial phase: Phase 3
ATC code: V03AB35
SMILES: O=C(O)CCSCC1OC2OC3C(CSCCC(=O)O)OC(OC4C(CSCCC(=O)O)OC(OC5C(CSCCC(=O)O)OC(OC6C(CSCCC(=O)O)OC(OC7C(CSCCC(=O)O)OC(OC8C(CSCCC(=O)O)OC(OC9C(CSCCC(=O)O)OC(OC1C(O)C2O)C(O)C9O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 101
Group description: Sugammadex: At the conclusion of surgery neuromuscular blockade reversed with sugammadex
Eligibility criteria:
Inclusion Criteria:

Adult patients age 18 years of age or greater who are capable of giving consent
Undergoing surgical procedures of expected length 6 </= hours requiring NMB

Exclusion Criteria:

Pregnancy
History of documented anaphylaxis or contraindication to any of the study medications
Active coronary disease with a positive cardiac stress test
History of severe chronic obstructive pulmonary disease (COPD) defined as an FEV1 < 50% of predicted
Serum Creatinine >/= 2.0 mg/dL

Severe hepatic dysfunction accompanied by coagulopathy

Definition:
Known liver Disease AND
INR > 1.5 (except for patients on anticoagulants) AND
Platelet count <100,00/ul without other obvious cause
Chronic sustained release opioid for > 2 weeks duration pre op (in the 30 days prior to surgery)
Use of toremifene
Significant cognitive impairment or documented psychologic impairment
Myasthenia gravis or other neuromuscular disease
Patients who are not eligible for standard anesthetic induction, eg, those needing rapid sequence induction or awake fiberoptic bronchial intubation.
American Society of Anesthesiologists (ASA) Status > 3
Intervention: ULIPRISTAL ACETATE
Trial phase: Phase 3
SMILES: CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 65
Group description: 15mg ulipristal acetate (capsule) daily for 7 days

Ulipristal Acetate: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
Eligibility criteria:
Inclusion Criteria:

Women age 18-45
Implant placed >90 days and <3 years prior to enrollment
Patient complaint of bothersome irregular bleeding with implant
Willing to be abstinent or use condoms during study period
Willing to complete 30-day bleeding diary
Willing to be randomized to placebo or ulipristal acetate
Ability to send/receive SMS text message

Exclusion Criteria:

Non-English speaking
Implant placed >3 years prior to enrollment
Contraindication to ulipristal acetate (current use of barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's Wort, topiramate, known or suspected pregnancy, hypersensitivity to active substance or excipients, uterine/cervical/ovarian/breast cancer, severe asthma insufficiently controlled by oral glucocorticoids)
Inability or unwillingness to comply with medication protocol
Inability or unwillingness to comply with bleeding diary
Breastfeeding
Intervention: Velpatasvir
Trial phase: Phase 3
ATC code: J05AP55 | J05AP56
SMILES: COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: SOF/VEL/VOX (400/100/100 mg) fixed-dose combination (FDC) tablet once daily for 12 weeks
Eligibility criteria:
Key Inclusion Criteria:

Chronically HCV-infected males and non-pregnant/non-lactating females aged 18 years or older who did not achieve sustained virologic response (SVR) in a prior Gilead-sponsored HCV treatment study

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Simethicone
Trial phase: Phase 4
SMILES: CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 268
Group description: Simethicone solution + Polyethylenglycol were received as a bowel prep regimen
Eligibility criteria:
Inclusion Criteria:

Patients between the ages of 30-80 scheduled for screening colonoscopy.
Male and female patients
Ambulatory patients
Signed informed consent form

Exclusion Criteria:

Previous colonic surgery
Patient with mental/physical condition that impairs oral ingestion of preparation
Allergy or hypersensitivity to simethicone
Patients with limited mobility (bedridden patients)
Patients with gastrointestinal obstruction
Patients with gastroparesis
Intervention: OXYTOCIN
Trial phase: Phase 1 | Phase 2
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered

Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
Eligibility criteria:
Inclusion Criteria:

BMI 30-40 kg/m2
Sedentary (< 2 strenuous exercise/week)
Gait speed < 1 meter/second

Exclusion Criteria:

Diabetes (ADA criteria)
Heart disease (MI or New York Heart Classification grade III-IV)
Poorly controlled hypertension (SBP > 170 or DBP >95 mm/Hg)
Anemia (Hematocrit <34%)
Renal Disease (Serum Creatinine >1.4, abnormal serum sodium levels, abnormal urinalysis, or physical exam findings indicative of fluid imbalance; individuals with underlying disorder of sodium/water balance, such as SIADH, diabetes insipidus, or psychogenic polydipsia)
Liver Disease (AST/ALT/AlkPhos > 2x upper limit of normal)
Use of systemic steroid, androgens, or anti-coagulants
Active/unstable conditions: inflammatory, thyroid, autoimmune, gastrointestinal (GI), hematologic, or neoplastic disorders
Individuals with underlying seizure disorder or underlying neurologic disorder that increases seizure risk
Cognitive impairment (MiniCog <3), unstable mental illness, substance abuse, or history of eating disorder
Intervention: Plecanatide
Trial phase: Phase 2
ATC code: A06AX07
SMILES: CC(C)CC(NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(N)CC(N)=O)CSSCC(NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(CC(N)=O)NC(=O)C(C(C)C)NC2=O)C(=O)NC(C(C)O)C(=O)NCC(=O)N1)C(=O)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 31
Group description: Taken orally once daily in the morning for 8 weeks

Plecanatide
Eligibility criteria:
Key Inclusion Criteria:

Male or female adolescents 12 to less than 18 years of age.
Diagnosed with CIC based on the Rome III criteria for child/adolescent functional constipation (Appendix A).
Patient is able to voluntarily provide written, signed, and dated (personally and via a legally authorized representative [LAR]) assent/informed consent as applicable to participate in the study.
Subject's parent/LAR demonstrates an understanding, ability, and willingness to fully comply with study procedures (e.g., accept venipuncture, willing and able to swallow tablets, accept urine drug screen for opiates) and restrictions.

Key Exclusion Criteria:

The patient has a mental age <4 years in the investigator's opinion.
The patient has previously been diagnosed with anorectal malformations, neurological deficits, or anatomical anomalies that would constitute a predisposition to constipation.
The patient currently requires iron supplements, amitriptyline, or other tricyclic antidepressants for depression, opioid-containing medications or compounds for pain, or has other conditions that require medications known to cause constipation. A patient with an onset of constipation prior to the use of these medications and who has been on a stable dose for at least 8 weeks prior to Screening might be considered eligible for this study if the investigator deems these medications do not significantly contribute to the patient's constipation. Screening of these patients needs to be approved by the medical monitor and the sponsor.

The patient, if female of childbearing potential (defined as postmenarche), does not agree to practice 1 of the following medically acceptable methods of birth control throughout the study:

Hormonal methods such as oral, implantable, injectable, vaginal ring, or transdermal contraceptives for a minimum of 1 full cycle (based on the patient's usual menstrual cycle period) before study drug administration.
Total abstinence from sexual intercourse since the last menses before study drug administration.
Intrauterine device.
Double barrier method (condoms, sponge, or diaphragm with spermicidal jellies or cream.
The patient follows a diet not considered normal by the investigator for the patient's age, relative to variety of food, caloric content, and quantity. The patient must have been on a stable diet for at least 30 days weeks prior to Screening.
The patient's mobility or normal exercise tolerance is compromised in the investigator's opinion.
The patient has a history of an eating disorder.
Intervention: Plecanatide
Trial phase: Phase 2
ATC code: A06AX07
SMILES: CC(C)CC(NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(N)CC(N)=O)CSSCC(NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(CC(N)=O)NC(=O)C(C(C)C)NC2=O)C(=O)NC(C(C)O)C(=O)NCC(=O)N1)C(=O)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 30
Group description: Taken orally once daily in the morning for 8 weeks

Plecanatide
Eligibility criteria:
Key Inclusion Criteria:

Male or female adolescents 12 to less than 18 years of age.
Diagnosed with CIC based on the Rome III criteria for child/adolescent functional constipation (Appendix A).
Patient is able to voluntarily provide written, signed, and dated (personally and via a legally authorized representative [LAR]) assent/informed consent as applicable to participate in the study.
Subject's parent/LAR demonstrates an understanding, ability, and willingness to fully comply with study procedures (e.g., accept venipuncture, willing and able to swallow tablets, accept urine drug screen for opiates) and restrictions.

Key Exclusion Criteria:

The patient has a mental age <4 years in the investigator's opinion.
The patient has previously been diagnosed with anorectal malformations, neurological deficits, or anatomical anomalies that would constitute a predisposition to constipation.
The patient currently requires iron supplements, amitriptyline, or other tricyclic antidepressants for depression, opioid-containing medications or compounds for pain, or has other conditions that require medications known to cause constipation. A patient with an onset of constipation prior to the use of these medications and who has been on a stable dose for at least 8 weeks prior to Screening might be considered eligible for this study if the investigator deems these medications do not significantly contribute to the patient's constipation. Screening of these patients needs to be approved by the medical monitor and the sponsor.

The patient, if female of childbearing potential (defined as postmenarche), does not agree to practice 1 of the following medically acceptable methods of birth control throughout the study:

Hormonal methods such as oral, implantable, injectable, vaginal ring, or transdermal contraceptives for a minimum of 1 full cycle (based on the patient's usual menstrual cycle period) before study drug administration.
Total abstinence from sexual intercourse since the last menses before study drug administration.
Intrauterine device.
Double barrier method (condoms, sponge, or diaphragm with spermicidal jellies or cream.
The patient follows a diet not considered normal by the investigator for the patient's age, relative to variety of food, caloric content, and quantity. The patient must have been on a stable diet for at least 30 days weeks prior to Screening.
The patient's mobility or normal exercise tolerance is compromised in the investigator's opinion.
The patient has a history of an eating disorder.